The scientific staff behind C4Pain has published more than 1600 scientific papers and has more than 25 years of experience in the field. C4Pain offers a comprehensive mechanism based drug screening program where modulation of pain and inflammatory mechanisms are evaluated quantitatively by the most advanced human bio-markers. C4Pain’s technological platform of advanced translational pain bio-marke
rs and surrogate pain models provides the basis for mechanism based proof-of-concept studies in healthy volunteers and pain patients. The surrogate models are unique as healthy volunteers may transiently experience the same symptoms (e.g. hyperalgesia or allodynia) as pain patients. Surrogate models may therefore act as proxies for clinical symptoms/mechanisms and the effect of compounds on such manifestations can be evaluated quantitatively. Proof-of-concept studies in small groups of volunteers or selected patient populations help target validation of new and existing compounds for the treatment of various pain and inflammatory conditions. A mechanism based understanding (validating target) helps to plan successful large clinical trials. In addition to planning and executing healthy volunteer and clinical trials (phase I, II, III, VI) C4Pain provides:
Design volunteer/patient trials based on pre-clinical data and recommend/develop/validate the translational bio-markers needed. "Fast track" mechanism based proof-of-concept service including the scientific advises needed for planning successful clinical development programs. Services related to the interpretation of the results obtained from the trials including how to translate the results into large clinical trials. Complete development packages from early to late phase trials speeding up the development process in an efficient and cost-effective manner. In addition to planning and executing healthy volunteer and clinical trials (phase I, II, III, VI) C4Pain provides:
1. Design volunteer/patient trials based on pre-clinical data and recommend/develop/validate the translational bio-markers needed.
2. "Fast track" mechanism based proof-of-concept service including the scientific advises needed for planning successful clinical development programs.
3. Services related to the interpretation of the results obtained from the trials including how to translate the results into large clinical trials.
4.
